---
title: "BioDlink Sets Out Board Composition and Key Committee Roles"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284463461.md"
description: "BioDlink International Company Limited has announced its board composition and the roles of its members, emphasizing structured corporate governance. The board includes an executive chairperson, a non-executive director, and independent non-executive directors. Key committees include Audit and Connected Transactions Review, chaired by Xin Fan, and Strategy and ESG, led by Ulf Grawunder. The governance structure aligns with Hong Kong listing standards, with a focus on balancing management input and independent oversight. The company is listed under stock code 1875 and operates in the biopharmaceutical sector."
datetime: "2026-04-28T23:03:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284463461.md)
  - [en](https://longbridge.com/en/news/284463461.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284463461.md)
---

# BioDlink Sets Out Board Composition and Key Committee Roles

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has issued an announcement.

BioDlink International Company Limited has announced the current composition of its board of directors and clarified the roles and functions of each member. The company has also detailed the makeup of its four key board committees—Audit and Connected Transactions Review, Remuneration, Nomination and Strategy and ESG—assigning chairperson and member responsibilities among its executive, non-executive and independent non-executive directors, underscoring its focus on structured corporate governance.

The Audit and Connected Transactions Review Committee will be chaired by independent non-executive director Xin Fan, while the Strategy and ESG Committee will be led by independent non-executive director Ulf Grawunder. Executive chairperson Dr. Jincai Li and non-executive director Xiaojie Xi will serve in various committee member roles, indicating a distribution of oversight duties intended to balance management input with independent supervision.

**More about TOT BIOPHARM International Co. Ltd.**

BioDlink International Company Limited, listed in Hong Kong under stock code 1875, operates in the biopharmaceutical sector. The company is overseen by a board that includes an executive chairperson, a non-executive director and several independent non-executive directors, reflecting a governance structure aligned with Hong Kong listing standards.

**Average Trading Volume:** 2,431,970

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$3.57B

### Related Stocks

- [01875.HK](https://longbridge.com/en/quote/01875.HK.md)

## Related News & Research

- [Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility | SCNI Stock News](https://longbridge.com/en/news/287052426.md)
- [SAMSUNG UNION LEADER : EXPECTS WAGE DEAL TO GAIN APPROVAL BY UNION MEMBERS](https://longbridge.com/en/news/287082370.md)
- [SAMSUNG UNION LEADER: AGREED ON HOW TO DISTRIBUTE PROFIT TO LOSS-MAKING BUSINESSES](https://longbridge.com/en/news/287081730.md)
- [Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors | IMUX Stock News](https://longbridge.com/en/news/286894992.md)
- [ZAWYA: KIB Group, represented by KIB Invest, acts as Joint Lead Manager in landmark $700mln Sukuk issuance by First Abu Dhabi Bank](https://longbridge.com/en/news/287054139.md)